RESUMO
Nitrofurantoin is an antimicrobial drug that has been used in the treatment of lower urinary tract infections for more than 50 years. Despite its long use, surprisingly little is known of the pharmacokinetics of nitrofurantoin, whereas this is essential to optimize patient treatment. We developed a novel analytical method for the quantification of nitrofurantoin in plasma and urine using ultra-high performance liquid chromatography and diode array detection to allow pharmacokinetic studies in these two matrices. The sample preparation method consisted of protein precipitation for plasma and liquid-liquid extraction for urine. 100⯵L was needed for the sample preparation. Furazolidone was used as internal standard. Gradient chromatographic separation was performed on a HSS-T3 column. UV detection was performed at a wavelength of 369â¯nm. The analysis time was 5â¯min. The method was successfully validated according to the FDA-guidelines (2018). Linearity was confirmed over a concentration range from 50 to 1250⯵g/L in plasma and from 4 to 200â¯mg/L in urine (r2 > 0.95). Validation results of five QC concentrations for plasma and urine, respectively, are for within-day accuracy <± 13% in both matrices, for between-day accuracy <± 7% and <± 9%, for within-day precision <10% and <4% and for between-day precision <10% and <5%. Plasma samples are stable for seven days at 4⯰C, and for 2 years at -20⯰Câ¯and-80⯰C. Urine samples are stable for at least seven days at 4⯰C and at room temperature and for 2 years at -20⯰Câ¯andat -80⯰C, except from the lower concentrated samples, which are only stable at -80⯰C. All samples were kept from daylight using amber colored glassware. The presented method meets all validation requirements and was successfully used in a clinical study where the pharmacokinetics of nitrofurantoin were investigated in healthy volunteers. The easy sample preparation method and the short analysis time make this method suitable for use during routine clinical practice to study the pharmacokinetics of nitrofurantoin.
Assuntos
Anti-Infecciosos Urinários/sangue , Anti-Infecciosos Urinários/urina , Cromatografia Líquida de Alta Pressão , Nitrofurantoína/sangue , Nitrofurantoína/urina , Bioensaio , Calibragem , Feminino , Humanos , Modelos Lineares , Extração Líquido-Líquido , Plasma , Reprodutibilidade dos Testes , Temperatura , Estados Unidos , United States Food and Drug Administration , Infecções Urinárias/tratamento farmacológicoRESUMO
The aim of this study was to determine the influence of feed on the pharmacokinetics of flumequine (FLU) administered to broiler chickens as follows: directly into the crop (10 mg/kg of BW) of fasted (group I/control) and non-fasted chickens (group II), or administered continu- ously with drinking water (1 g/L for 72 h) and with unlimited access to feed (group III). Plasma concentration of FLU was determined by high-performance liquid chromatography with fluo- rescence detection. In group II, a significant decrease in the maximum concentration (Cmax = 2.13±0.7 µg/mL) and the area under the concentration curve from zero to infinity (AUC0â∞ = 7.47±2.41 µg·h/mL) was noted as compared to the control group (Cmax = 4.11±1.68 µg/mL and AUC0â∞ = 18.17±6.85 µg·h/mL, respectively). In group III, the decrease in AUC was signifi- cant only in the first 3 hours (AUC0â3 = 5.02±1.34 µg·h/mL) as compared to the control group (AUC0â3 = 7.79±3.29 µg·h/mL). The results indicate that feed reduced the bioavailability of FLU from the gastrointestinal tract by at least 50% after the administration of a single oral dose. However, continuous administration of FLU with drinking water could compensate for the feed-induced decrease in absorption after single oral dose.
Assuntos
Anti-Infecciosos Urinários/farmacocinética , Galinhas/sangue , Fluoroquinolonas/farmacocinética , Administração Oral , Ração Animal , Animais , Anti-Infecciosos Urinários/administração & dosagem , Anti-Infecciosos Urinários/sangue , Área Sob a Curva , Disponibilidade Biológica , Galinhas/metabolismo , Esquema de Medicação , Feminino , Fluoroquinolonas/administração & dosagem , Fluoroquinolonas/sangue , Interações Alimento-Droga , Meia-Vida , MasculinoRESUMO
In this study, the pharmacokinetic profile of flumequine (FMQ) was investigated in blunt snout bream (Megalobrama amblycephala) after intravascular (3 mg/kg body weight (b.w.)) and oral (50 mg/kg b.w.) administrations. The plasma samples were determinedby ultra-performance liquid chromatography (UPLC) with fluorescence detection. After intravascular administration, plasma concentration-time curves were best described by a two-compartment open model. The distribution half-life (t1/2α ), elimination half-life (t1/2ß ), and area under the concentration-time curve (AUC) of blunt snout bream were 0.6 h, 25.0 h, and 10612.7 h·µg/L, respectively. After oral administration, a two-compartment open model with first-order absorption was also best fit the data of plasma. The t1/2α , t1/2ß , peak concentration (Cmax ), time-to-peak concentration (Tmax ), and AUC of blunt snout bream were estimated to be 2.5 h, 19.7 h, 3946.5 µg/L, 1.4 h, and 56618.1 h. µg/L, respectively. The oral bioavailability (F) was 32.0%. The pharmacokinetics of FMQ in blunt snout bream displayed low bioavailability, rapid absorption, and rapid elimination.
Assuntos
Anti-Infecciosos Urinários/farmacocinética , Cyprinidae/metabolismo , Fluoroquinolonas/farmacocinética , Administração Intravenosa , Administração Oral , Animais , Anti-Infecciosos Urinários/administração & dosagem , Anti-Infecciosos Urinários/sangue , Disponibilidade Biológica , Cyprinidae/sangue , Fluoroquinolonas/administração & dosagem , Fluoroquinolonas/sangueRESUMO
PURPOSE: A new generic formulation of cycloserine has been developed in China but the pharmacokinetic properties of cycloserine in the Chinese population have not been reported. The aim of our study was to evaluate the pharmacokinetic properties and tolerability of single and multiple oral administrations of cycloserine capsules in healthy Chinese volunteers. METHODS: This open-label, single- and multiple-dose 3-way crossover study was conducted in healthy Chinese volunteers. Subjects were randomized to receive a single dose of cycloserine (250, 500, or 1000 mg) in separate trial periods, with a 1-week washout between periods. Those allocated to the 250-mg dose continued into the multiple-dose phase, in which they received 250 mg BID for 5 consecutive days. During the single-dose phase, blood samples were collected at regular intervals from 0 to 72 hours after drug administration and the concentrations of cycloserine were determined using LC-MS/MS. During the multiple-dose phase, blood samples were obtained before drug administration on Days 4, 5, and 6 to determine the Cmin at steady state. On Day 6, blood samples were also collected from 0 to 72 hours after drug administration. Pharmacokinetic parameters were estimated using noncompartmental methods. Tolerability was determined using clinical evaluation and monitoring of adverse events. FINDINGS: The study enrolled 12 healthy Chinese volunteers (6 men: mean [SD] age = 23.0 [2.6] years, weight = 60.2 [6.2] kg, height = 170.0 [3.0] cm, and body mass index = 20.7 [1.7]; 6 women: mean [SD] age = 25.3 [1.4] years, weight = 51.5 [3.3] kg, height = 160.0 [4.0] cm, and body mass index = 20.1 [0.9]). After administration of a single dose, cycloserine was rapidly absorbed, reaching peak plasma concentrations approximately 0.84 hours after oral administration, and t½ in plasma was about 13.0 hours. The geometric mean (SD) Cmax value increased in proportion to cycloserine dose, from 19.42 (5.89) to 84.76 (21.74) mg/L, and the geometric mean (SD) AUC0-72h value increased from 264.16 (133.37) to 1153.87 (522.16) mg·h/L in the range of a 250- to 1000-mg dose. After administration of multiple doses of cycloserine 250 mg BID, the mean (SD) t½ was 13.56 (4.38) hours, the apparent total clearance of the drug from plasma after oral administration was 1.02 (0.42) L/h, and the apparent volume of distribution was 18.22 (5.25) L, which were comparable with those after single dosing. The accumulation index was 2.19 (0.51), and the fluctuation was 1.05 (0.35). Results of the t tests of Cmax and AUC found no significant differences between the male and female groups. No serious adverse events were reported, and there were no discontinuations due to adverse events. IMPLICATIONS: The pharmacokinetic properties of cycloserine were linear at doses from 250 mg to 1000 mg. After multiple doses, the pharmacokinetic properties of cycloserine were consistent with those after single doses. At the doses studied, cycloserine appears to be well tolerated in these healthy volunteers. Chinese Clinical Trials registration: ChiCTR-TTRCC-13003982.
Assuntos
Anti-Infecciosos Urinários/sangue , Anti-Infecciosos Urinários/farmacologia , Ciclosserina/sangue , Ciclosserina/farmacologia , Administração Oral , Adulto , Área Sob a Curva , China , Estudos Cross-Over , Feminino , Voluntários Saudáveis , Humanos , Masculino , Adulto JovemRESUMO
BACKGROUND: To identify changes in cefoperazone/sulbactam penetration into cerebrospinal fluid (CSF) after craniotomy and to investigate preliminarily whether cefoperazone/sulbactam CSF concentration can reach therapeutic level when administered intravenously after neurosurgical operation. METHODS: Neurosurgical patients with an indwelling ventricular drainage pipe who received prophylactic cefoperazone/sulbactam for the treatment of intracranial infection were received a cefoperazone/sulbactam 2:1, 3.0-g infusion for 3 hours every 6 hours for 24 h. Venous blood and CSF specimens were collected to determine cefoperazone/sulbactam concentrations. RESULTS: The cefoperazone and sulbactam concentrations in serum were highest at the second hour (237.54 ± 336.72 mg/L and 66.52 ± 80.38 mg/L, respectively) and then decreased. The cefoperazone and sulbactam concentrations in CSF were highest at the 4th hour (39.22 ± 75.55 mg/L and 6.24 ± 8.35 mg/L, respectively) and then decreased. CSF penetration measured by the ratio of peak concentrations (CSF/serum) was 8.6% ± 7.2% for cefoperazone and 13.5% ± 11.9% for sulbactam, CSF penetration measured by the ratio of trough concentrations (CSF/serum) was 13.4% ± 5.3% for cefoperazone and 106.5% ± 87.5% for sulbactam. CSF penetration represented by the ratio of area under the curve (AUC) of CSF and serum was 14.5% for cefoperazone and 22.6% for sulbactam. Neurosurgical impairment of the blood-brain barrier may improve the CSF penetration of these drugs, but it is difficult to reach the MIC90 of resistant bacteria. If single intravenous administration time was extended to 3 hours, the serum concentrations of drugs were able to meet the PK/PD standard (T> MIC%> 50%) for treating common, highly resistant bacteria. CONCLUSIONS: The CSF penetration of cefoperazone/sulbactam may be enhanced after neurosurgical impairment of the blood-brain barrier. This study is a pilot research of cefoperazone/sulbactam using in neurosurgical individuals, However, it needs to be confirmed by further large-scale studies.
Assuntos
Cefoperazona/sangue , Cefoperazona/líquido cefalorraquidiano , Craniotomia , Sulbactam/sangue , Sulbactam/líquido cefalorraquidiano , Adulto , Idoso , Anti-Infecciosos Urinários/administração & dosagem , Anti-Infecciosos Urinários/sangue , Anti-Infecciosos Urinários/líquido cefalorraquidiano , Cefoperazona/administração & dosagem , Combinação de Medicamentos , Feminino , Humanos , Infusões Intravenosas , Masculino , Pessoa de Meia-Idade , Projetos Piloto , Teste Bactericida do Soro , Sulbactam/administração & dosagem , Fatores de TempoRESUMO
A reliable, selective and sensitive LC-MS/MS assay has been proposed for the determination of nitrofurantoin in human plasma. The analyte and nitrofurazone were extracted from 100 µL of human plasma via SPE on Strata-X 33 µm extraction cartridges. Chromatography was done on a BDS Hypersil C18 (100 mm × 4.6 mm, 5 µm) column under isocratic conditions. Quantitation was done using the multiple reaction monitoring (MRM) mode for deprotonated precursor to product ion transitions of nitrofurantoin (m/z 237.0 â 151.8) and nitrofurazone (m/z 197.0 â 123.9). The limit of detection and the lowest limit of quantitation of the method were 0.25 ng mL-1 and 5.00 ng mL-1, respectively, with a linear dynamic range of 5.00-1500 ng mL-1 for nitrofurantoin. The intra- -batch and inter-batch precision (RSD, %) was ≤ 5.8 %, while the mean extraction recovery was > 92 %. The method was successfully applied to a bioequivalence study of a 100 mg nitrofurantoin capsule formulation in 36 healthy subjects.
Assuntos
Cromatografia Líquida/métodos , Nitrofurantoína , Nitrofurazona , Espectrometria de Massas em Tandem/métodos , Adulto , Anti-Infecciosos Urinários/sangue , Anti-Infecciosos Urinários/química , Anti-Infecciosos Urinários/farmacocinética , Cápsulas , Monitoramento de Medicamentos/métodos , Humanos , Nitrofurantoína/sangue , Nitrofurantoína/química , Nitrofurantoína/farmacocinética , Nitrofurazona/sangue , Nitrofurazona/química , Nitrofurazona/farmacocinética , Reprodutibilidade dos Testes , Extração em Fase Sólida/métodos , Equivalência TerapêuticaRESUMO
PURPOSE: The aim of this study was to determine in vivo inhibition by the isoflavones genistein and daidzein of nitrofurantoin (NTF), a well-known substrate of the ABC transporter BCRP/ABCG2. METHODS: MDCKII cells and their human BCRP- and murine Bcrp1-transduced subclones were used to establish inhibition in transepithelial transport assays. Bcrp1(-/-) and wild-type mice were coadministered with nitrofurantoin (20 mg/kg) and a mixture of genistein (100 mg/kg) and daidzein (100 mg/kg). RESULTS: Transepithelial NFT transport was inhibited by the isoflavones. Plasma concentration of NTF at 30 min was 1.7-fold higher (p ≤ 0.05) in wild-type mice after isoflavone administration. AUC values were not significantly different. BCRP/ABCG2-mediated secretion into milk was inhibited since milk/plasma ratios were lower in wild-type mice with isoflavones (7.1 ± 4.2 vs 4.2 ± 1.6, p ≤ 0.05). NTF bile levels were significantly decreased by isoflavone administration in wild-type animals (8.8 ± 3.4 µg/ml with isoflavones vs 3.7 ± 3.3 µg/ml without isoflavones). CONCLUSION: Our data showed that in vivo interaction of high doses of soy isoflavones with BCRP substrates may affect plasma levels but the main effect occurs in specific target organs, in our case, liver and mammary glands.
Assuntos
Transportadores de Cassetes de Ligação de ATP/antagonistas & inibidores , Anti-Infecciosos Urinários/farmacocinética , Genisteína/farmacologia , Isoflavonas/farmacologia , Proteínas de Neoplasias/antagonistas & inibidores , Nitrofurantoína/farmacocinética , Membro 2 da Subfamília G de Transportadores de Cassetes de Ligação de ATP , Transportadores de Cassetes de Ligação de ATP/genética , Animais , Anti-Infecciosos Urinários/sangue , Bile/química , Transporte Biológico/efeitos dos fármacos , Técnicas de Cultura de Células , Linhagem Celular , Cromatografia Líquida de Alta Pressão , Cães , Feminino , Humanos , Lactação/metabolismo , Camundongos , Camundongos Knockout , Leite/química , Proteínas de Neoplasias/genética , Nitrofurantoína/sangueRESUMO
Studies on residues in milk used for human consumption have increased due to health concerns and priority interest in the control of potentially risky drugs. The protein BCRP/ABCG2, present in the mammary epithelia, actively extrudes drugs into milk and can be modulated by isoflavones. Nitrofurantoin is a specific BCRP substrate which is actively excreted into milk by this transporter. In this research, we studied nitrofurantoin transport into milk in four experimental groups: G1-calves fed forage with isoflavones; G2-calves fed forage with isoflavones and administered exogenous genistein and daidzein; G3-calves fed forage without isoflavones; G4-calves fed forage without isoflavones and administered exogenous genistein and daidzein. Results show increased levels of nitrofurantoin in milk from calves without isoflavones (G3) and decreased nitrofurantoin residues in milk when isoflavones were present, either by forage (G1 and G2) or by exogenous administration (G4). The values of C(max) in milk were significantly lower in those groups with isoflavones in forage (G1, G2). Plasma levels were low and unmodified among the groups. Inter-individual variation was high. All these results seem to point to a feasible control of drug secretion into milk through isoflavones in the diet when the drug is a good BCRP/ABCG2 substrate.
Assuntos
Anti-Infecciosos Urinários/farmacocinética , Genisteína/farmacologia , Isoflavonas/farmacologia , Leite/química , Nitrofurantoína/farmacocinética , Administração Oral , Animais , Anti-Infecciosos Urinários/análise , Anti-Infecciosos Urinários/sangue , Cromatografia Líquida de Alta Pressão , Feminino , Nitrofurantoína/análise , Nitrofurantoína/sangue , Ovinos/metabolismoRESUMO
We investigated the effect of pregnancy on nitrofurantoin (NFT) disposition in wild-type and Bcrp1(-/-) mice. Pregnant and non-pregnant mice were administered NFT intravenously (5 mg/kg) or orally (10 mg/kg). Blood samples were collected at various times (5-60 min) after drug administration, plasma NFT concentrations determined by HPLC/UV, and pharmacokinetic parameters estimated. Dose-normalized area under the plasma concentration-time curve (AUC), terminal plasma half-life (T(1/2)), total plasma clearance (CL), and steady-state volume of distribution (V(ss)) of intravenous NFT in wild-type or Bcrp1(-/-) mice were not altered by pregnancy. After oral administration, pregnancy did not affect dose-normalized AUC of NFT in wild-type mice; however, dose-normalized AUC in Bcrp1(-/-) mice was decreased by approximately 70% by pregnancy. In conclusion, since Bcrp1 plays a minor role in the systemic clearance of NFT in female mice, pregnancy did not affect disposition of intravenous NFT despite the fact that Bcrp1 expression in the liver and kidney of mice is significantly induced by pregnancy. On the other hand, pregnancy may affect expression and activity of certain intestinal efflux transporters and/or metabolic enzymes in Bcrp1(-/-) mice, resulting in a drastic decrease in the systemic exposure of oral NFT in pregnant Bcrp1(-/-) mice.
Assuntos
Transportadores de Cassetes de Ligação de ATP/metabolismo , Anti-Infecciosos Urinários/farmacocinética , Nitrofurantoína/farmacocinética , Membro 2 da Subfamília G de Transportadores de Cassetes de Ligação de ATP , Transportadores de Cassetes de Ligação de ATP/genética , Animais , Anti-Infecciosos Urinários/administração & dosagem , Anti-Infecciosos Urinários/sangue , Área Sob a Curva , Cromatografia Líquida de Alta Pressão , Relação Dose-Resposta a Droga , Feminino , Meia-Vida , Injeções Intravenosas , Taxa de Depuração Metabólica , Camundongos , Camundongos Knockout , Nitrofurantoína/administração & dosagem , Nitrofurantoína/sangue , Gravidez , Espectrofotometria Ultravioleta , Distribuição Tecidual/efeitos dos fármacosRESUMO
The efflux transporter, the breast cancer resistance protein (BCRP), is most abundantly expressed in the apical membrane of the placental syncytiotrophoblasts, indicating that it could play an important role in protecting the fetus by limiting xenobiotic/drug penetration across the placental barrier. In the present study, we examined whether Bcrp1, the murine homolog of human BCRP, limits fetal distribution of the model BCRP/Bcrp1 substrate, nitrofurantoin (NFT), in the pregnant mouse. NFT was administered i.v. to FVB wild-type and Bcrp1(-/-) pregnant mice. The maternal plasma samples and fetuses were collected at various times (5-60 min) after drug administration. The NFT concentrations in the maternal plasma samples and homogenates of fetal tissues were determined by a high-performance liquid chromatography/UV assay. Although the maternal plasma area under the concentration-time curve (AUC) of NFT in the Bcrp1(-/-) pregnant mice (97.4 +/- 10.0 microg . min/ml plasma) was only slightly (but significantly) higher than that in the wild-type pregnant mice (78.4 +/- 6.0 microg . min/ml plasma), the fetal AUC of NFT in the Bcrp1(-/-) pregnant mice (1493.0 +/- 235.3 ng . min/g of fetus) was approximately 5 times greater than that in the wild-type pregnant mice (298.6 +/- 77.4 ng . min/g of fetus). These results clearly suggest that Bcrp1 significantly limits fetal distribution of NFT in the pregnant mouse, but has only a minor effect on the systemic clearance of the drug.
Assuntos
Transportadores de Cassetes de Ligação de ATP/metabolismo , Anti-Infecciosos Urinários/farmacocinética , Feto/metabolismo , Troca Materno-Fetal , Nitrofurantoína/farmacocinética , Placenta/metabolismo , Membro 2 da Subfamília G de Transportadores de Cassetes de Ligação de ATP , Transportadores de Cassetes de Ligação de ATP/genética , Animais , Anti-Infecciosos Urinários/administração & dosagem , Anti-Infecciosos Urinários/sangue , Área Sob a Curva , Cromatografia Líquida de Alta Pressão , Feminino , Injeções Intravenosas , Taxa de Depuração Metabólica , Camundongos , Camundongos Knockout , Nitrofurantoína/administração & dosagem , Nitrofurantoína/sangue , Gravidez , Espectrofotometria Ultravioleta , Distribuição TecidualRESUMO
OBJECTIVE: The combination of chloroquine and methylene blue is potentially effective for the treatment of chloroquine-resistant malaria caused by Plasmodium falciparum. The aim of this study was to investigate whether methylene blue influences the pharmacokinetics of chloroquine. METHODS: In a randomized, placebo-controlled, parallel group design, a 3-day course of therapeutic oral doses of chloroquine (total 2.5 g in male, 1.875 g in female participants) with oral co-administration of placebo or 130 mg methylene blue twice daily for 3 days was administered to 24 healthy individuals. Chloroquine, desethylchloroquine, and methylene blue concentrations were determined by means of HPLC/UV or LC/MS/MS assays in whole blood, plasma, and urine for 28 days after the last dose. RESULTS: During methylene blue exposure, the area under the chloroquine whole blood concentration-time curve normalized to body weight (AUC(0-24 h)/BW) yielded a trend of reduction (249+/-98.2 h mug l(-1) kg(-1) versus 315+/-65.0 h mug l(-1) kg(-1), P=0.06). The AUC(0-24 h)/BW of desethylchloroquine was reduced by 35% (104+/-40.3 h mug l(-1) kg(-1) versus 159+/-66.6 h mug l(-1) kg(-1), P=0.03), whereas the metabolic ratio between chloroquine and desethylchloroquine remained unchanged (2.25+/-0.49 versus 1.95+/-0.42, P=0.17). The renal clearance of chloroquine and the ratio between chloroquine in whole blood and plasma remained unchanged (P>0.1). CONCLUSION: Oral co-administration of methylene blue appears to result in a small reduction of chloroquine exposure which is not expected to be clinically relevant and thus represents no concern for further development as an anti-malarial combination.
Assuntos
Anti-Infecciosos Urinários/farmacologia , Antimaláricos/farmacocinética , Cloroquina/análogos & derivados , Cloroquina/farmacocinética , Azul de Metileno/farmacologia , Administração Oral , Adulto , Anti-Infecciosos Urinários/sangue , Antimaláricos/sangue , Antimaláricos/urina , Área Sob a Curva , Cloroquina/sangue , Cloroquina/urina , Interações Medicamentosas , Feminino , Meia-Vida , Humanos , Malária Falciparum/tratamento farmacológico , MasculinoRESUMO
The distribution of trimethoprim (TMP) and sulfadiazine (SDZ) into subcutaneously implanted noninfected tissue chambers was studied in healthy adult ponies. Six ponies were given an oral TMP/SDZ paste formulation at a dose of 5 mg/kg TMP and 25 mg/kg SDZ at 12 h intervals for 2 days in order to reach steady-state concentrations. Plasma concentrations and tissue chamber fluid (TCF) concentrations of both drugs were measured at regular intervals during a period commencing 24 h after the last oral administration. The peak concentration of TMP (mean +/- SD) was 2.92 +/- 0.86 microg/mL for plasma and 1.09 +/- 0.25 microg/mL for TCF. For SDZ, the mean peak concentration was 40.20 +/- 14.74 microg/mL for plasma and 23.48 +/- 5.84 microg/mL for TCF. TMP peak concentrations in plasma were reached at 3.17 +/- 03.48 h and those in TCF at 7.33 +/- 03.72 h. SDZ peak concentrations in plasma were reached at 1.83 +/- 02.04 h and those in TCF at 8.00 +/- 03.10 h. Concentrations of TMP and SDZ in TCF remained above the generally accepted breakpoint for susceptibility (0.5/9.5 for the TMP/SDZ combination) for 12 h. Therefore, in ponies oral administration of TMP/SDZ at a dose rate of 30 mg/kg given twice daily in the form of a paste should be appropriate for effective treatment of infections caused by susceptible bacteria.
Assuntos
Anti-Infecciosos Urinários/farmacocinética , Sulfadiazina/farmacocinética , Trimetoprima/farmacocinética , Administração Oral , Animais , Anti-Infecciosos Urinários/administração & dosagem , Anti-Infecciosos Urinários/sangue , Área Sob a Curva , Cromatografia Líquida de Alta Pressão , Combinação de Medicamentos , Feminino , Meia-Vida , Cavalos , Masculino , Sulfadiazina/administração & dosagem , Sulfadiazina/sangue , Distribuição Tecidual , Trimetoprima/administração & dosagem , Trimetoprima/sangueRESUMO
A differential-pulse adsorptive stripping voltammetric method for the determination of trace amounts of the antibacterial lomefloxacin is proposed. By using an accumulation potential of -0.30 V and a 2 min accumulation time, the linear concentration range of application was 1.0-10.0 ng ml(-1) of lomefloxacin, with a relative standard deviation of 3.8% (for a level of 5.0 ng ml(-1)) and a detection limit of 0.3 ng ml(-1). The method was applied to determination of lomefloxacin in human urine and serum samples. It was validated using HPLC as a reference method. Recovery levels of the method reached 100% in all cases.
Assuntos
Anti-Infecciosos Urinários/urina , Anti-Infecciosos/urina , Cromatografia Líquida de Alta Pressão/métodos , Fluoroquinolonas , Quinolonas/urina , Anti-Infecciosos/sangue , Anti-Infecciosos Urinários/sangue , Humanos , Concentração de Íons de Hidrogênio , Quinolonas/sangueRESUMO
In urinary tract infection (UTI), the aim of antimicrobial chemotherapy is either to attenuate the virulence of infective micro-organisms, to influence the interaction between germs and host or to kill bacteria. In 25 females (aged 49.8+/-14.7 years) with chronic UTI, parameters of inflammation (CRP, alpha 2-globulin, leukocytes, ESR) as well as renal function were analyzed under the treatment with ofloxacin 2 x 200 mg. Subsequently, bacterial attachment, bacterial count, leukocytes, antibody-coated bacteria (ACB), immunoglobulin (Ig) G, albumin, a2-microglobulin, Tamm Horsfall protein, secretory IgA (sIgA) and lysozyme were determined in urine. The micro-organisms were examined with regard to the expression of hemolysin, aerobactin, P-fimbriae and according to their plasmid profile. Ofloxacin serum levels were analyzed once prior to, on day 6 during and on day 3 after drug administration. In all cases, the acute clinical symptoms had disappeared after 10 days of treatment, all bacteria were eliminated, and the parameters of inflammation in serum and urine had returned to normal. On the sixth day of therapy, no expression of P-fimbriae was detectable in the Escherichia coli strains isolated, and the attachment rate decreased from 42+/-30.9% to 11.1+/-18.1%. The sIgA level rose from 42.6+68.5 prior to therapy to 88.8+/-136.8 mmol/l on day 3 after therapy; acute symptoms of UTI did not recur in any case during the period of 1 year.
Assuntos
Anti-Infecciosos Urinários/uso terapêutico , Ofloxacino/uso terapêutico , Infecções Urinárias/tratamento farmacológico , Adulto , Idoso , Anti-Infecciosos Urinários/sangue , Anti-Infecciosos Urinários/farmacologia , Anti-Infecciosos Urinários/urina , Aderência Bacteriana/efeitos dos fármacos , Contagem de Colônia Microbiana , Feminino , Humanos , Imunoglobulina A Secretora/metabolismo , Pessoa de Meia-Idade , Mucoproteínas/urina , Ofloxacino/sangue , Ofloxacino/farmacologia , Ofloxacino/urina , Uromodulina , VirulênciaAssuntos
Anti-Infecciosos Urinários/sangue , Fluoroquinolonas , Quinolizinas/sangue , Ovinos/sangue , Administração Oral , Animais , Anti-Infecciosos Urinários/administração & dosagem , Cromatografia Líquida de Alta Pressão/métodos , Injeções Intravenosas/veterinária , Quinolizinas/administração & dosagem , EstereoisomerismoRESUMO
This study was carried out to determine the concentrations of sulfadoxine and trimethoprim in plasma, lymph, and some tissues in goats after administration of a single recommended therapeutic dose. Five healthy, adult Angora goats were used. The drug combination, containing 200 mg sulfadoxine and 40 mg trimethoprim per millilitre, was given as a single IM injection at the recommended dose level, 15 mg/kg body weight for sulfadoxine and 3 mg/kg body weight for trimethoprim. The goats were slaughtered 24 hours after drug administration and samples were taken from liver, bone marrow, pelvic limb muscles, hepatic, thoracic duct, and the pelvic limb lymph fluids for analysis of drug concentrations by HPLC. The concentrations of trimethoprim in bone marrow, liver, pelvic limb muscles, hepatic lymph, the pelvic limb lymph, and thoracic duct lymph were found to be 6, 5, 4, 2, 5 and 15 times higher than those of plasma, respectively. Although the sulfadoxine concentrations in bone marrow, pelvic limb muscles, and liver were 2, 3 and 2 times higher than the plasma concentrations, respectively, the sulfadoxine concentrations in hepatic lymph, the pelvic limb lymph, and thoracic duct lymph were lower than those of plasma. The results show that the trimethoprim concentrations in lymph fluids were quite similar to those in tissues. However, the sulfadoxine concentrations in lymph fluids were different in each tissue.
Assuntos
Anti-Infecciosos Urinários/farmacocinética , Cabras/metabolismo , Sulfadoxina/farmacocinética , Trimetoprima/farmacocinética , Animais , Anti-Infecciosos Urinários/administração & dosagem , Anti-Infecciosos Urinários/sangue , Medula Óssea/metabolismo , Cromatografia Líquida de Alta Pressão/veterinária , Combinação de Medicamentos , Cabras/sangue , Injeções Intramusculares/veterinária , Fígado/metabolismo , Linfa/metabolismo , Músculo Esquelético/metabolismo , Sulfadoxina/administração & dosagem , Sulfadoxina/sangue , Trimetoprima/administração & dosagem , Trimetoprima/sangueRESUMO
Healthy gilts and market-ready hogs were administered a single intramuscular (IM) injection of Borgal, a commercial formulation of trimethoprim-sulfadoxine (TMP-SDX), once or twice daily. The objectives were to determine if a newly-developed high-performance liquid chromatographic (HPLC) method would be suitable for measuring the residual concentrations of TMP in the plasma of these live animals, and to determine if the administration of this veterinary drug would leave measurable residues in their plasma and tissues at slaughter. Plasma and tissue concentrations of SDX and TMP from these animals were determined over a period of 14 d using thin-layer chromatography/densitometry (TLCD), and the newly-developed HPLC method, respectively. The lowest detectable limit (LDL) for SDX in plasma and tissue was 20 ppb by TLCD. The HPLC method had a LDL of 5 ppb for TMP in plasma and tissue. Both methods were then used to provide baseline data on the absorption and depletion of TMP and SDX from these healthy animals. It was observed that both TMP and SDX were readily absorbed into the blood and tissues, but TMP was eliminated much faster than SDX. No TMP residues were detected in the plasma of any of the gilts at and beyond 21 h after drug administration. Also, no TMP residues were detected in the plasma of any of the market-ready hogs 24 h after drug administration at either the label dose or twice the label dose. Sulfadoxine residues at concentrations above the maximum residue limit (MRL) of 100 ppb were, however, detected in the plasma, muscle, kidney, liver, and injection sites of hogs slaughtered 1 and 3 d after a single IM administration at the label dose. Although SDX residues were still detectable in the lungs, kidney, liver and plasma of some hogs 10 d after administration of the label dose and twice the label dose, these were below the MRL. Postmortem examination revealed necrosis and inflammation at the injection sites, but no visible deposits of the injected drug.
Assuntos
Anti-Infecciosos Urinários/análise , Rim/química , Fígado/química , Pulmão/química , Músculo Esquelético/química , Sulfadoxina/análise , Sulfanilamidas/análise , Suínos/metabolismo , Trimetoprima/análise , Animais , Anti-Infecciosos Urinários/administração & dosagem , Anti-Infecciosos Urinários/sangue , Cromatografia Líquida de Alta Pressão/veterinária , Cromatografia em Camada Fina/veterinária , Feminino , Injeções Intramusculares , Sulfadoxina/administração & dosagem , Sulfadoxina/sangue , Sulfanilamidas/administração & dosagem , Sulfanilamidas/sangue , Trimetoprima/administração & dosagem , Trimetoprima/sangueRESUMO
Protein binding kinetics of basic antimicrobials including trimethoprim (TMP), erythromycin (EM), lincomycin (LM) and clindamycin (CM) were studied using porcine plasma, albumin and alpha 1-acid glycoprotein (AGP). Rosenthal plots of these basic drugs in porcine plasma suggest saturable and non-saturable binding. Dissociation constants (kd) and binding capacity (Bmax) for saturable binding were as follows: TMP, kd = 8.58 mumol/L, Bmax = 5.26 mumol/L; EM, kd = 2.72 mumol/L, Bmax = 3.06 mumol/L, LM, kd = 3.96 mumol/L, Bmax = 6.58 mumol/L and CM, kd = 4.43 mumol/L, Bmax = 21.7 mumol/L. The proportionality constants (Bmax2/kd2) for non-saturable binding were 0.29 in TMP, 0.52 in EM, 0.17 in LM and 3.2 in CM. The kds of the drugs in porcine AGP solution were determined by a fluorescence quenching method, using 1-anilino-8-naphthalene sulphonate (ANS) as a fluorescent probe: 9.51 mumol/L in TMP, 1.89 mumol/L in EM, 4.48 mumol/L in LM and 9.69 mumol/L, in CM. Comparable kd values between porcine plasma and AGP solution indicated that AGP is a major saturable binder in porcine plasma. Binding property to porcine albumin presented linearity, showing the following proportionality constants: 0.23 in TMP, 0.38 in EM, 0.01 in LM and 0.76 in CM. The comparable proportionality constants of TMP and EM between porcine plasma and albumin solution indicate that albumin is a major non-saturable binder, whereas proportionality constants of LM and CM in albumin solution compared to those in porcine plasma were low, implying another non-saturable binder, i.e. lipoprotein. Simulation curve of drug-binding percentage vs. AGP concentrations showed that in pigs under a pathologic state, or during early growth stage with high AGP levels, AGP could be a main contributor to drug-plasma protein binding for all drugs examined. The increase of AGP from normal to pathological concentrations induced a decrease in the unbound fraction: LM > CM > EM > TMP in order of AGP contribution to drug binding. Therefore, the disposition and efficacy of basic antimicrobials which bind to AGP with high affinity could be markedly influenced by altered AGP levels, implying AGP contribution to pharmacokinetics and pharmacodynamics.
Assuntos
Antibacterianos/sangue , Anti-Infecciosos Urinários/sangue , Orosomucoide/metabolismo , Albumina Sérica/metabolismo , Naftalenossulfonato de Anilina/química , Animais , Antibacterianos/administração & dosagem , Antibacterianos/farmacocinética , Anti-Infecciosos Urinários/administração & dosagem , Anti-Infecciosos Urinários/farmacocinética , Clindamicina/administração & dosagem , Clindamicina/sangue , Clindamicina/farmacocinética , Eritromicina/administração & dosagem , Eritromicina/sangue , Eritromicina/farmacocinética , Corantes Fluorescentes/química , Lincomicina/administração & dosagem , Lincomicina/sangue , Lincomicina/farmacocinética , Ligação Proteica , Espectrometria de Fluorescência/veterinária , Suínos , Porco Miniatura , Trimetoprima/administração & dosagem , Trimetoprima/sangue , Trimetoprima/farmacocinéticaRESUMO
A highly sensitive and selective HPLC method was developed and validated for the determination of nitrofurantoin in human plasma and urine. The method involves the liquid-liquid extraction of drug and internal standard from plasma with ethyl acetate followed by evaporation and reconstitution in mobile phase. Urine samples were simply diluted with purified water. UV detection was done at 370 nm. The limit of quantification for nitrofurantoin in plasma was 0.010 micrograms/ml. In urine nitrofurantoin could be quantified down to 0.380 microgram/ml. Linearity was proven over the whole calibration range in plasma (2.48-0.0100 microgram/ml) as well as in urine (187 micrograms/ml-0.380 microgram/ml). The method was validated according to Good Laboratory Practice guidelines and its suitability was demonstrated by analysis of samples from a pharmacokinetic study.